Market Summary
USD11.72-1.54
Market Closed-11.61%
VERV Stock Price
VERV RSI Chart
VERV Valuation
VERV Price/Sales (Trailing)
VERV Profitability
VERV Fundamentals
VERV Revenue
VERV Earnings
Price Action
52 Week Range
11.2540.88
(Low)(High)
Last 7 days
9.7%
Last 30 days
1.1%
Last 90 days
-29.3%
Trailing 12 Months
-61.2%
VERV Financial Health
VERV Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for VERV
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2022-12-14 | Bellinger Andrew | acquired | 103,320 | 2.87 | 36,000 | cso & cmo |
2022-12-01 | Bellinger Andrew | sold | -19,851 | 22.95 | -865 | cso & cmo |
2022-11-29 | Dorval Allison | acquired | - | - | 1,875 | chief financial officer |
2022-11-29 | Dorval Allison | sold | -12,243 | 22.1 | -554 | chief financial officer |
2022-11-04 | GV 2017 GP, L.L.C. | sold | -1,512,810 | 31.1386 | -48,583 | - |
2022-11-04 | Yeshwant Krishna | sold | -1,512,810 | 31.1386 | -48,583 | - |
2022-11-04 | Yeshwant Krishna | sold | - | - | -48,583 | - |
2022-11-04 | GV 2017 GP, L.L.C. | sold | -1,512,800 | 31.1386 | -48,583 | - |
2022-11-04 | GV 2017 GP, L.L.C. | sold | - | - | -48,583 | - |
2022-11-03 | GV 2017 GP, L.L.C. | sold | - | - | -49,569 | - |
Which funds bought or sold VERV recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Jefferies Group LLC | new | - | 430,921 | 430,921 | -% |
2023-09-20 | BARCLAYS PLC | added | 11.46 | 706,000 | 2,275,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -1.45 | 3,912 | 17,811 | -% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | added | 10.78 | 299,503 | 979,406 | -% |
2023-08-16 | Nuveen Asset Management, LLC | added | 9.44 | 980,201 | 3,298,200 | -% |
2023-08-15 | GOLDMAN SACHS GROUP INC | added | 1.57 | 1,216,080 | 5,007,710 | -% |
2023-08-15 | LAZARD ASSET MANAGEMENT LLC | added | 2.94 | 9,000 | 35,000 | -% |
2023-08-15 | WELLS FARGO & COMPANY/MN | added | 14.93 | 375,124 | 1,133,830 | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | reduced | -3.94 | 282,950 | 1,418,810 | -% |
2023-08-14 | IFP Advisors, Inc | new | - | 304 | 304 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Verve Therapeutics
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 14, 2023 | singer james r | 8.1% | 5e+06 | SC 13G/A | |
| Feb 14, 2023 | casdin capital, llc | 3.7% | 2,290,571 | SC 13G/A | |
| Feb 13, 2023 | arch venture fund x, l.p. | - | 0 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 6.19% | 3,812,024 | SC 13G | |
| Feb 09, 2023 | fmr llc | - | 0 | SC 13G/A | |
| Feb 07, 2023 | state street corp | 7.26% | 4,471,049 | SC 13G | |
| Feb 06, 2023 | wellington management group llp | 1.39% | 859,102 | SC 13G/A | |
| Feb 14, 2022 | gv 2017, l.p. | 13.12% | 6,320,905 | SC 13G | |
| Feb 14, 2022 | casdin capital, llc | 6.5% | 3,138,167 | SC 13G/A | |
| Feb 09, 2022 | fmr llc | - | 0 | SC 13G/A |
Recent SEC filings of Verve Therapeutics
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 3 | Insider Trading | |
| Aug 10, 2023 | 8-K | Current Report | |
| Aug 10, 2023 | 10-Q | Quarterly Report |
Verve Therapeutics News
Returns for VERV
Cumulative Returns on VERV
Risks for VERV
What is the probability of a big loss on VERV?
88.3%
Probability that Verve Therapeutics stock will be more than 20% underwater in next one year
88.3%
Probability that Verve Therapeutics stock will be more than 30% underwater in next one year.
86.7%
Probability that Verve Therapeutics stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does VERV drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Verve Therapeutics was unfortunately bought at previous high price.
Drawdowns
Financials for Verve Therapeutics
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||
|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 |
| Revenue | 47.4% | 5,438,000 | 3,689,500 | 1,941,000 | - | - |
| Operating Expenses | 9.5% | 213,850,000 | 195,366,000 | 167,628,000 | 151,446,000 | 130,159,000 |
| S&GA Expenses | 10.2% | 46,999,000 | 42,650,000 | 37,533,000 | 32,695,000 | 29,110,000 |
| R&D Expenses | 9.3% | 166,851,000 | 152,716,000 | 130,095,000 | 118,751,000 | 101,049,000 |
| EBITDA | 100.0% | - | -153,917,000 | -154,530,000 | - | - |
| EBITDA Margin | 100.0% | - | -34.51 | -79.61 | - | - |
| Earnings Before Taxes | -Infinity% | -215,228,000 | - | -157,334,000 | - | -163,784,000 |
| EBT Margin | 100.0% | - | -35.28 | -81.06 | - | - |
| Net Income | -7.3% | -192,233,000 | -179,196,000 | -157,387,000 | -147,639,000 | -125,198,000 |
| Net Income Margin | 100.0% | - | -40.18 | -81.09 | -39.73 | - |
| Free Cashflow | 100.0% | - | -151,620,000 | -135,564,000 | -126,728,000 | -117,273,000 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2020Q4 |
| Assets | -7.1% | 589 | 634 | 679 | 673 | 324 | 349 | 384 | 411 | 427 | 78.00 |
| Current Assets | -8.6% | 473 | 518 | 563 | 562 | 299 | 329 | 367 | 394 | 420 | 74.00 |
| Cash Equivalents | -16.4% | 70.00 | 84.00 | 115 | 277 | 73.00 | 91.00 | 70.00 | 148 | 387 | 9.00 |
| Net PPE | 0.9% | 21.00 | 21.00 | 19.00 | 15.00 | 12.00 | 11.00 | 7.00 | 7.00 | 6.00 | 4.00 |
| Liabilities | -0.8% | 124 | 125 | 128 | 125 | 28.00 | 18.00 | 27.00 | 26.00 | 21.00 | 17.00 |
| Current Liabilities | -1.6% | 33.00 | 34.00 | 35.00 | 29.00 | 26.00 | 15.00 | 22.00 | 20.00 | 9.00 | 7.00 |
| Shareholder's Equity | -8.7% | 465 | 509 | 551 | 548 | 296 | 331 | 357 | 385 | 405 | - |
| Retained Earnings | -13.6% | -450 | -396 | -344 | -303 | -257 | -217 | -186 | -155 | -132 | -66.54 |
| Additional Paid-In Capital | 1.1% | 916 | 906 | 896 | 852 | 555 | 549 | 544 | 540 | 538 | 3.00 |
| Shares Outstanding | 0.3% | 62.00 | 62.00 | 62.00 | 60.00 | 49.00 | 49.00 | 49.00 | 48.00 | 8.00 | 3.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
| Cashflow From Operations | -15.4% | -159 | -137 | -122 | -117 | -109 | -96.25 | -77.88 | -64.81 | -49.78 | -48.59 | -35.26 | -25.30 | -27.93 | -7.44 |
| Share Based Compensation | 12.8% | 30.00 | 26.00 | 22.00 | 19.00 | 15.00 | 11.00 | 7.00 | 5.00 | 3.00 | 2.00 | 1.00 | 1.00 | 0.00 | 0.00 |
| Cashflow From Investing | 12.6% | -175 | -200 | -155 | -44.63 | -201 | -190 | -239 | -170 | 39.00 | 28.00 | -51.13 | -10.87 | -120 | -12.76 |
| Cashflow From Financing | 0.2% | 331 | 330 | 329 | 291 | 1.00 | 284 | 377 | 376 | 377 | 125 | 93.00 | - | 185 | 18.00 |
VERV Income Statement
2023-06-30Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Collaboration Revenue | $ 2,093 | $ 0 | $ 3,497 | $ 0 |
| Operating expenses: | ||||
| Research and development | 47,260 | 33,125 | 94,370 | 57,614 |
| General and administrative | 13,416 | 9,067 | 25,969 | 16,503 |
| Total operating expenses | 60,676 | 42,192 | 120,339 | 74,117 |
| Loss from operations | (58,583) | (42,192) | (116,842) | (74,117) |
| Other (expense) income: | ||||
| Change in fair value of success payment liability | (662) | 938 | 76 | 2,615 |
| Interest and other income, net | 5,438 | 308 | 10,984 | 390 |
| Total other income, net | 4,776 | 1,246 | 11,060 | 3,005 |
| Loss before provision for income taxes | (53,807) | (40,946) | (105,782) | (71,112) |
| Provision for income taxes | (176) | 0 | (176) | 0 |
| Net loss | $ (53,983) | $ (40,946) | $ (105,958) | $ (71,112) |
| Net loss per common share attributable to common stockholders, basic | $ (0.87) | $ (0.84) | $ (1.71) | $ (1.46) |
| Net loss per common share attributable to common stockholders, diluted | $ (0.87) | $ (0.84) | $ (1.71) | $ (1.46) |
| Weighted-average common shares used in net loss per share attributable to common stockholders, basic | 61,953,992 | 48,674,873 | 61,871,158 | 48,623,330 |
| Weighted-average common shares used in net loss per share attributable to common stockholders, diluted | 61,953,992 | 48,674,873 | 61,871,158 | 48,623,330 |
| Comprehensive Loss: | ||||
| Net loss | $ (53,983) | $ (40,946) | $ (105,958) | $ (71,112) |
| Other comprehensive income (loss): | ||||
| Unrealized income (loss) on marketable securities | (517) | (206) | (60) | (710) |
| Comprehensive loss | $ (54,500) | $ (41,152) | $ (106,018) | $ (71,822) |
VERV Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 70,042 | $ 115,412 |
| Marketable securities | 392,434 | 439,396 |
| Collaboration receivable | 2,093 | 1,012 |
| Prepaid expenses and other current assets | 8,497 | 7,339 |
| Total current assets | 473,066 | 563,159 |
| Property and equipment, net | 21,252 | 18,778 |
| Restricted cash | 4,824 | 4,824 |
| Operating lease right-of-use assets | 88,766 | 91,877 |
| Other long term assets | 1,223 | 585 |
| Total assets | 589,131 | 679,223 |
| Current liabilities: | ||
| Accounts payable | 3,146 | 2,424 |
| Accrued expenses | 19,839 | 20,767 |
| Lease liability, current portion | 10,046 | 11,904 |
| Total current liabilities | 33,031 | 35,095 |
| Long-term lease liability | 67,819 | 70,014 |
| Success Payment Liability | 2,809 | 2,885 |
| Deferred revenue non-current | 20,014 | 20,014 |
| Other long term liabilities | 236 | 283 |
| Total liabilities | 123,909 | 128,291 |
| Commitments and contingencies (See Note 7 and Note 8) | ||
| Stockholders' equity: | ||
| Preferred stock, $0.001 par value; 5,000,000 shares authorized; no shares issued and outstanding | 0 | 0 |
| Common stock, $0.001 par value; 200,000,000 shares authorized, 62,064,279 and 61,730,816 shares issued and outstanding at June 30, 2023 and December 31, 2022, respectively | 62 | 62 |
| Additional paid-in capital | 916,109 | 895,801 |
| Accumulated other comprehensive loss | (754) | (694) |
| Accumulated deficit | (450,195) | (344,237) |
| Total stockholders equity | 465,222 | 550,932 |
| Total liabilities and stockholders' equity | $ 589,131 | $ 679,223 |
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.